Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
J. Clin. Oncol 2021 Oct 07;[EPub Ahead of Print], WG Wierda, JN Allan, T Siddiqi, TJ Kipps, S Opat, A Tedeschi, XC Badoux, BJ Kuss, S Jackson, C Moreno, R Jacobs, JM Pagel, I Flinn, Y Pak, C Zhou, E Szafer-Glusman, J Ninomoto, JP Dean, DF James, P Ghia, CS TamFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.